☆ 4.7 Article

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas

BIOMEDICINES (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

Identification of patients at high risk of secondary extramedullary multiple myeloma development

Martin Stork et al.

Summary: The study identified younger age, high lactate dehydrogenase levels, extensive osteolytic activity, immunoglobulin A or the non-secretory type of MM as main risk factors for secondary EMD development in MM patients. Additionally, MM patients with specific risk factors associated with secondary EMD development were found to have a more aggressive disease course before the development of secondary EMD.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Michele Cavo et al.

Summary: In this study, we explored the impact of minimal residual disease (MRD) on relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM). The results showed that achieving complete response or better (>= CR) and MRD negativity were associated with improved progression-free survival (PFS) in both RRMM and TIE NDMM patients, regardless of the type of therapy or disease setting.

BLOOD (2022)

Add to Collection

Letter Oncology

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

Tomas Jelinek et al.

LEUKEMIA (2022)

Add to Collection

Review Oncology

Extramedullary disease in multiple myeloma: a systematic literature review

Joan Blade et al.

Summary: Extramedullary involvement is an aggressive form of multiple myeloma, with varied typical sites and incidence rates. Patients with EMD have poor prognosis and lower treatment efficacy. The lack of prospective studies limits strong recommendations for treatment approaches.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Article Oncology

Proteomic analysis of the bone marrow microenvironment in extramedullary multiple myeloma patients

Jana Gregorova et al.

Summary: This study identified different expression levels of cytokines in the bone marrow (BM) plasma of multiple myeloma (MM) and extramedullary disease (EMD) patients. These cytokines were found to be significantly associated with clinicopathological features of MM/EMD patients and play important roles in various signaling pathways and cellular processes. The results confirm the crucial role of the BM microenvironment in MM pathogenesis and highlight the importance of cytokines in disease progression and EMD development.

NEOPLASMA (2022)

Add to Collection

Article Oncology

Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma

Elena Zamagni et al.

Summary: This study analyzed the metabolic response of PET/CT scans in newly diagnosed transplantation-eligible patients with multiple myeloma, and found that FL and bone marrow FDG uptake lower than liver background could predict prolonged progression-free survival and overall survival, suggesting their value as standardized criteria for PET complete metabolic response in patients with MM.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Hematology

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

Laura Rosinol et al.

Summary: This review identifies two types of soft-tissue involvement in multiple myeloma: EMD and PS. EMD disease is associated with high-risk cytogenetics, therapy resistance, and worse prognosis. For patients with PS involvement, a proteasome inhibitor-based regimen may be the best option.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Review Oncology

Roadmap to cure multiple myeloma

Paula Rodriguez-Otero et al.

Summary: In order to achieve a cure for multiple myeloma, five complementary strategies are proposed: increasing knowledge about disease pathogenesis, using undetectable measurable residual disease as the new endpoint of therapy, treating disease causation instead of symptomatology, using the most active scheme, and investigating experimental therapies.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Article Oncology

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma

JingSong He et al.

Summary: This study found that multiple sites of EMB and/or EME are independent poor prognostic factors for newly diagnosed MM patients treated with bortezomib-based regimens, while a single site of EMB does not affect patients' survival. Multiple sites of EMB and/or EME are prognostic predictors affecting PFS and OS in newly diagnosed MM patients.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

Extramedullary disease in multiple myeloma

Radhika Bansal et al.

Summary: Extramedullary multiple myeloma (EMD) is a challenging disease from therapeutic and biological perspectives, with unclear pathogenetic mechanisms. In the era of novel agents, there is a rising incidence of EMD, but lack of standard treatment approaches.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Hematology

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

Vittorio Montefusco et al.

HAEMATOLOGICA (2020)

Add to Collection

Article Hematology

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

Meral Beksac et al.

HAEMATOLOGICA (2020)

Add to Collection

Article Medicine, General & Internal

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Maria-Victoria Mateos et al.

LANCET (2020)

Add to Collection

Article Oncology

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response

Nadine Abdallah et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Article Hematology

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

Habte Yimer et al.

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Add to Collection

Review Hematology

Extramedullary disease in multiple myeloma - controversies and future directions

Sabina Sevcikova et al.

BLOOD REVIEWS (2019)

Add to Collection

Article Medicine, General & Internal

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

T. Facon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Hematology

Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Nico Gagelmann et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Review Oncology

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

Ola Landgren et al.

LEUKEMIA (2019)

Add to Collection

Article Hematology

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

Nico Gagelmann et al.

HAEMATOLOGICA (2018)

Add to Collection

Article Hematology

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

Nico Gagelmann et al.

HAEMATOLOGICA (2018)

Add to Collection

Editorial Material Oncology

HAEMATOLOGICAL CANCER Where are we now with the treatment of multiple myeloma?

Gareth J. Morgan et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Multiple myeloma

Shaji K. Kumar et al.

NATURE REVIEWS DISEASE PRIMERS (2017)

Add to Collection

Article Hematology

Cytogenetics in multiple myeloma patients progressing into extramedullary disease

Lenka Besse et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2016)

Add to Collection

Article Hematology

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld et al.

BLOOD (2016)

Add to Collection

Article Hematology

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation

Mathew Weinstock et al.

BRITISH JOURNAL OF HAEMATOLOGY (2015)

Add to Collection

Article Hematology

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

Cindy Varga et al.

BRITISH JOURNAL OF HAEMATOLOGY (2015)

Add to Collection

Article Biotechnology & Applied Microbiology

Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance

Xiaoyan Qu et al.

BIOMED RESEARCH INTERNATIONAL (2015)

Add to Collection

Article Hematology

Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens

Noa Biran et al.

AMERICAN JOURNAL OF HEMATOLOGY (2014)

Add to Collection

Article Hematology

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

Ludek Pour et al.

HAEMATOLOGICA (2014)

Add to Collection

Review Oncology

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

S. Vincent Rajkumar et al.

LANCET ONCOLOGY (2014)

Add to Collection

Article Oncology

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

B. Paiva et al.

LEUKEMIA (2013)

Add to Collection

Article Hematology

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Saad Z. Usmani et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)

Add to Collection

Review Oncology

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

K. Detweiler Short et al.

LEUKEMIA (2011)

Add to Collection

Article Oncology

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients

M. Varettoni et al.

ANNALS OF ONCOLOGY (2010)

Add to Collection

Article Hematology

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

Milena Sant et al.

BLOOD (2010)

Add to Collection

Article Oncology

The impact of extramedullary disease at presentation on the outcome of myeloma

Ping Wu et al.

LEUKEMIA & LYMPHOMA (2009)

Add to Collection

Article Oncology

The role of anatomic and functional staging in myeloma: Description of Durie/Salmon PLUS staging system

Brian G. M. Durie

EUROPEAN JOURNAL OF CANCER (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.